Downregulation of MiR-30a is associated with poor prognosis in lung cancer

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 2514-2520

  Tang, Ruixue ^a   Liang, Lu ^a   Luo, Dianzhong ^a   Feng, Zhenbo ^a   Huang, Qiuxia ^a   He, Rongquan ^a   Gan, Tingqing ^a   Yang, Lihua ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; MicroRNAs; Non small cell lung; Prognosis; Real time polymerase chain reaction; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 30A; UNCLASSIFIED DRUG; MIRN30 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MRNA EXPRESSION ASSAY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME; TUMOR VOLUME; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; YOUNG ADULT;

EID: 84940393118     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894372     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. Cancer J Clin, 2015; 65(1): 5-29
2. Soini Y: Tight junctions in lung cancer and lung metastasis: a review. Int J Clin Exp Pathol, 2012; 5(2): 126-36
3. Di Leva G, Briskin D, Croce CM: MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci, 2012; 117(2): 202-16
4. Qian B, Nag SA, Su Y et al: miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets, 2013; 13(5): 519-41
5. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res, 2004; 14(10A): 1902-10
6. Fu J, Xu X, Kang L et al: miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun, 2014; 445(2): 314-19
7. Dai H, Kang B, Zuo D, Zuo G: [Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of SMCC-7721 human hepatocellular carcinoma cells]. Zhonghua Gan Zang Bing Za Zhi, 2014; 22(12): 915-20 [in Chinese]
8. Zhang Q, Tang Q, Qin D et al: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis. Mol Cell Biol, 2015; 35(6): 988-1000
9. Wang HY, Li YY, Fu S et al: MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Exp Biol Med (Maywood), 2014; 239(7): 891-98
10. Katz B, Reis ST, Viana NI et al: Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One, 2014; 9(11): e113700
11. Tsukamoto O, Miura K, Mishima H et al: Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol, 2014; 132(3): 715-21
12. Sand M, Skrygan M, Georgas D et al: Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci, 2012; 68(3): 119-26
13. Hu Z, Chen X, Zhao Y et al: Serum microRNA signatures identified in a genome- wide serum microRNA expression profiling predict survival of nonsmall- cell lung cancer. J Clin Oncol, 2010; 28(10): 1721-26
14. Markou A, Tsaroucha EG, Kaklamanis L et al: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem, 2008; 54(10): 1696-704
15. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res, 2010; 70(1): 36-45
16. Voortman J, Goto A, Mendiboure J et al: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res, 2010; 70(21): 8288-98
17. Yanaihara N, Caplen N, Bowman E et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006; 9(3): 189-98
18. Yu SL, Chen HY, Chang GC et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell, 2008; 13(1): 48-57
19. Jiang BY, Zhang XC, Su J et al: BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer, 2013; 12: 61
20. Kumarswamy R, Mudduluru G, Ceppi P et al: MicroRNA-30a inhibits epithelial- to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer, 2012; 130(9): 2044-53
21. Liu K, Guo L, Guo Y et al: AEG-1 3'-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity. Eur J Cell Biol, 2015; 94(1): 22-31
22. Chen G, Kronenberger P, Teugels E, De Greve J: Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online, 2011; 13: 1
23. Chen G, Kronenberger P, Teugels E et al: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med, 2012; 10: 28
24. Chen G, Kronenberger P, Teugels E et al: Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 2013; 431(3): 623-29
25. Chen G, Kronenberger P, Umelo IA et al: Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem, 2010; 398(2): 266-68
26. Chen G, Noor A, Kronenberger P et al: Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One, 2013; 8(3): e59708
27. Chen G, Umelo IA, Lv S et al: miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One, 2013; 8(3): e60317
28. Rong M, He R, Dang Y, Chen G: Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci, 2014; 119(1): 19-24
29. Zhang X, Li P, Rong M et al: MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: clinical analysis of 125 patients. Tohoku J Exp Med, 2015; 235(3): 161-69
30. Duffy MJ: Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med, 2007; 18(3): 175-84
31. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell, 2009; 139(5): 871-90
32. Braun JE, Huntzinger E, Izaurralde E: The role of GW182 proteins in miRNA- mediated gene silencing. Adv Exp Med Biol, 2013; 768: 147-63
33. Erkan M, Weis N, Pan Z et al: Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer, 2010; 9: 88
34. Ni JQ, Jiang XH, Tang WH: Relationship between pancreatic stellate cells and pancreatic cancer. Shijie Huaren Xiaohua Zazhi, 2008; (33): 3782-86
35. Taira N, Kawabata T, Ichi T et al: Long-term survival after surgical treatment of metachronous bilateral adrenal metastases of non-small cell lung carcinoma. Am J Case Rep, 2014; 15: 444-46